Agilon Health Under Investigation for Securities Fraud Violations
ByAinvest
Tuesday, Aug 12, 2025 3:26 am ET1min read
AGL--
The Schall Law Firm, Pomerantz LLP, and Bragar Eagel & Squire, P.C. have all announced investigations into potential securities fraud violations by Agilon and its officers [1][2][3]. These law firms are encouraging investors who suffered losses to contact them to discuss their legal rights.
The investigations focus on whether Agilon issued false or misleading statements and failed to disclose material information to investors. The company announced the resignation of Steven Sell and withdrew its full-year 2025 financial guidance in the same press release, which may have contributed to the significant drop in its stock price [1][2].
Agilon's second-quarter 2025 financial results also missed expectations, reporting a net loss of $0.25 per share and revenue of $1.4 billion, down 6% year-over-year [4]. The company cited ongoing leadership transition, shifts in market dynamics, and the rollout of new performance visibility tools for suspending its full-year 2025 guidance [4].
Investors who purchased or acquired Agilon shares and suffered a loss are encouraged to contact the law firms conducting the investigations to discuss their legal rights. The Schall Law Firm can be reached at 310-301-3335 or via email at bschall@schallfirm.com [1]. Pomerantz LLP can be contacted at 646-581-9980, ext. 7980 or via email at newaction@pomlaw.com [2]. Bragar Eagel & Squire, P.C. can be reached at (212) 355-4648 or via email at investigations@bespc.com [3].
References:
[1] https://www.businesswire.com/news/home/20250804620055/en/AGL-Investors-Have-Opportunity-to-Join-agilon-health-inc.-Fraud-Investigation-with-the-Schall-Law-Firm
[2] https://www.marketscreener.com/news/pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-agilon-health-inc-agl-ce7c5ed2d18cf62c
[3] https://www.morningstar.com/news/globe-newswire/9510146/agilon-alert-bragar-eagel-squire-pc-is-investigating-agilon-health-inc-on-behalf-of-agilon-stockholders-and-encourages-investors-to-contact-the-firm
[4] https://ih.advfn.com/market-news/article/14072/agilon-health-shares-plunge-after-q2-miss-leadership-shakeup-and-suspended-guidance
EXC--
MORN--
Agilon Health is being investigated for securities fraud violations after the company's CEO and board director stepped down and withdrew its full-year 2025 earnings guidance. Shares of Agilon fell 27% in after-hours trading. The DJS Law Group is investigating claims on behalf of investors for potential violations of securities laws.
Agilon Health, Inc. (NYSE: AGL) is under scrutiny following the sudden resignation of its CEO and board director, Steven Sell, and the withdrawal of its full-year 2025 earnings guidance. The company's stock price plummeted by over 27% in after-hours trading on August 4, 2025 [1].The Schall Law Firm, Pomerantz LLP, and Bragar Eagel & Squire, P.C. have all announced investigations into potential securities fraud violations by Agilon and its officers [1][2][3]. These law firms are encouraging investors who suffered losses to contact them to discuss their legal rights.
The investigations focus on whether Agilon issued false or misleading statements and failed to disclose material information to investors. The company announced the resignation of Steven Sell and withdrew its full-year 2025 financial guidance in the same press release, which may have contributed to the significant drop in its stock price [1][2].
Agilon's second-quarter 2025 financial results also missed expectations, reporting a net loss of $0.25 per share and revenue of $1.4 billion, down 6% year-over-year [4]. The company cited ongoing leadership transition, shifts in market dynamics, and the rollout of new performance visibility tools for suspending its full-year 2025 guidance [4].
Investors who purchased or acquired Agilon shares and suffered a loss are encouraged to contact the law firms conducting the investigations to discuss their legal rights. The Schall Law Firm can be reached at 310-301-3335 or via email at bschall@schallfirm.com [1]. Pomerantz LLP can be contacted at 646-581-9980, ext. 7980 or via email at newaction@pomlaw.com [2]. Bragar Eagel & Squire, P.C. can be reached at (212) 355-4648 or via email at investigations@bespc.com [3].
References:
[1] https://www.businesswire.com/news/home/20250804620055/en/AGL-Investors-Have-Opportunity-to-Join-agilon-health-inc.-Fraud-Investigation-with-the-Schall-Law-Firm
[2] https://www.marketscreener.com/news/pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-agilon-health-inc-agl-ce7c5ed2d18cf62c
[3] https://www.morningstar.com/news/globe-newswire/9510146/agilon-alert-bragar-eagel-squire-pc-is-investigating-agilon-health-inc-on-behalf-of-agilon-stockholders-and-encourages-investors-to-contact-the-firm
[4] https://ih.advfn.com/market-news/article/14072/agilon-health-shares-plunge-after-q2-miss-leadership-shakeup-and-suspended-guidance
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet